These first copycat drugs, usually called me-too drugs by industry insiders, created a problem that has bedeviled the industry thereafter--the propensity for some of the newer versions of the drug ...

But interpreting patent law in a way that makes reach-through claims to drug target patents difficult to obtain actually may not be in the best interest of public health. The 'me-too' drug problem ...

those that include a single brand-name drug (typically new drugs, which have not yet attracted so-called me-too drugs). An incentive-price system can be used for the first two classes but is not ...